Managers

Sunstone backs Forendo

Forendo Pharma, a Finnish drug developer focused on women's health, has secured 5 million euros in funding. The investor was Sunstone Life Science Ventures. In addition to the funding, Claus Andersson, a general partner from Sunstone, joins Forendo Pharma's board of directors.

Secfi lands $6 mln Series A

Secfi, a financing provider for option exercise and holders of private company stock, has raised $6 million in Series A funding. Rucker Park Capital led the round.

Radiology Partners racks up $700 mln

El Segundo, California-based Radiology Partners, a radiology practice in the U.S., has raised about $700 million in funding. The backer was Starr Investment Holdings.

Medicixi raises 400 mln euros for third fund

Medicixi, a European life sciences investment firm, has closed its third fund at 400 million euros. The investors in Medicixi III include Novartis and Johnson & Johnson Innovation – JJDC, Inc. The fund will invest in early and late-stage biopharma companies.

Friday Letter: CalPERS' performance; 1H fundraising on a tear; and emerging manager roundup

I'm skeptical the good times will continue to roll, but it's hard to argue that against the enormous stores of capital that seem to be available. Plenty of funds are raising commitments from various LPs.

Emerging managers pull in $1.1 bln, led by Vida Ventures

Here's how Sierra Ventures added LPs and raised $215 mln for its 12th fund

Loeb.nyc backs OrthoSnap

Westbury, New York-based OrthoSnap, a maker of clear dental aligners, has secured an undisclosed amount of funding. The investor was Loeb.nyc. In addition to the funding, Michael Loeb, CEO of Loeb.nyc, will join OrthoSnap's board of directors.

DEARhealth takes in $6.8 mln

Los Angeles and Amsterdam-based DEARhealth, an AI health tech startup, has raised $6.8 million in funding. The investors were Philips Health Technology Ventures, Vesalius Biocapital III and Health Innovations.

Kronos Bio lands $105 mln Series A

San Mateo, California-based Kronos Bio, which is focused on researching and developing first-in-class therapies "that modulate historically undruggable targets," has secured $105 million in Series A funding. The investors included Vida Ventures LLC.